Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis.
Metabolomics of Neurodegenerative Diseases.
Resistant Strains of Enterotoxigenic Staphylococcus aureus; Unknown Risk for Multiple Sclerosis Exacerbation.
Evolution of myelin ultrastructure and the major structural myelin proteins.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of the Brain- Part 1.
Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System.
Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers.
Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients.
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
Comparing adherence rates to disease modifying therapies for multiple sclerosis in commercial enrollees and Part D beneficiaries.
Modulation of multiple sclerosis by sunlight exposure: Role of cis-urocanic acid.
Negative work events and accommodations in employed multiple sclerosis patients.
Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: Comparison of the results with that of multiple sclerosis patients.
Multiple sclerosis at Jordan University Hospital.
Comparison of serum levels of copper and zinc among multiple sclerosis patients and control group.
Distribution of CD4(pos) -, CD8(pos) - and Regulatory T Cells in the Upper and Lower Gastrointestinal Tract in Healthy Young Subjects.
Internal jugular veins out flow in patients with multiple sclerosis:a catheter venography study.
Remote Neurodegeneration: Multiple Actors for One Play.
Osthole augments therapeutic efficiency of neural stem cells-based therapy in experimental autoimmune encephalomyelitis.
Maternal Neurofascin-Specific Autoantibodies Bind to Structures of the Fetal Nervous System during Pregnancy, but Have No Long Term Effect on Development in the Rat.
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.
Is there any relation between chronic cerebrospinal venous insufficiency and multiple sclerosis? - a critical review.
The potential of epigenetic therapies in neurodegenerative diseases.
Neuropeptide Y protects cerebral cortical neurons by regulating microglial immune function.
Pages
« first
‹ previous
…
616
617
618
619
620
621
622
623
624
…
next ›
last »